INT160481

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 9
Disease Relevance 3.78
Pain Relevance 1.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
skin 2
ventral roots 1
keratinocytes 1
TRPV3 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 15 99.80 Very High Very High Very High
Dorsal horn 4 92.40 High High
Spinal cord 44 91.16 High High
diabetic neuropathy 32 89.80 High High
nociceptor 9 87.64 High High
dorsal root ganglion 128 85.76 High High
Peripheral nervous system 4 85.20 High High
qutenza 24 75.00 Quite High
Nerve growth factor 24 61.04 Quite High
Neuritis 4 56.92 Quite High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 100 99.84 Very High Very High Very High
Injury 80 98.76 Very High Very High Very High
Neuropathic Pain 60 96.32 Very High Very High Very High
Increased Venous Pressure Under Development 9 92.64 High High
Diabetic Neuropathy 32 89.80 High High
Ganglion Cysts 132 85.76 High High
Peripheral Neuropathy 4 81.12 Quite High
Frailty 4 66.24 Quite High
Nervous System Injury 36 65.00 Quite High
Demyelinating Disease 8 62.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Agonist-specific desensitization of endogenous TRPV3 was also found in HaCaT cells, which may be taken as a representative for the native system.
Negative_regulation (desensitization) of TRPV3
1) Confidence 0.59 Published 2009 Journal J Pharm Pharm Sci Section Body Doc Link 19470296 Disease Relevance 0 Pain Relevance 0
Our finding on agonist-induced desensitization of TRPV3 by some monoterpenoids displays a novel mechanism through which TRP channels could be functionally modulated.
Negative_regulation (desensitization) of TRPV3
2) Confidence 0.43 Published 2009 Journal J Pharm Pharm Sci Section Body Doc Link 19470296 Disease Relevance 0 Pain Relevance 0
RESULTS: We report here that prolonged exposure (5-15 minutes) of monoterpenoids results in agonist-specific desensitization of TRPV3.
Negative_regulation (desensitization) of TRPV3
3) Confidence 0.43 Published 2009 Journal J Pharm Pharm Sci Section Body Doc Link 19470296 Disease Relevance 0 Pain Relevance 0
Monoterpenoids induce agonist-specific desensitization of transient receptor potential vanilloid-3 (TRPV3) ion channels.
Negative_regulation (desensitization) of TRPV3 associated with agonist
4) Confidence 0.43 Published 2009 Journal J Pharm Pharm Sci Section Title Doc Link 19470296 Disease Relevance 0.09 Pain Relevance 0.22
Monoterpenoids induce agonist-specific desensitization of transient receptor potential vanilloid-3 (TRPV3) ion channels.
Negative_regulation (desensitization) of vanilloid-3 associated with agonist
5) Confidence 0.43 Published 2009 Journal J Pharm Pharm Sci Section Title Doc Link 19470296 Disease Relevance 0.09 Pain Relevance 0.22
Diabetic epidermis is known to be abnormally thin, so the trend we describe for decrease of TRPV3 in keratinocytes, may be related to changes of neurotrophins or other factors controlling skin differentiation and TRPV3 expression.
Negative_regulation (decrease) of TRPV3 in skin associated with diabetes mellitus
6) Confidence 0.40 Published 2007 Journal BMC Neurol Section Body Doc Link PMC1892784 Disease Relevance 0.60 Pain Relevance 0.12
Visual assessment of the intensity of TRPV3 and TRPV4 immunostaining in keratinocytes in diabetic skin showed a trend for decrease of TRPV3 [median (range) control 1.5 (1.0–2.5), diabetic 1.0 (0.5–2.0), p = 0.053; Fig 11] but not TRPV4 (not shown).


Negative_regulation (decrease) of TRPV3 in keratinocytes associated with diabetes mellitus
7) Confidence 0.40 Published 2007 Journal BMC Neurol Section Body Doc Link PMC1892784 Disease Relevance 1.06 Pain Relevance 0.14
Immunoreactivity for TRPV3 was detected in basal keratinocytes, with a significant decrease of TRPV3 in diabetic skin.
Negative_regulation (decrease) of TRPV3 in skin associated with diabetes mellitus
8) Confidence 0.40 Published 2007 Journal BMC Neurol Section Abstract Doc Link PMC1892784 Disease Relevance 1.30 Pain Relevance 0.62
TRPV3 immunoreactivity in the ventral roots was largely lost three to four weeks following injury.
Negative_regulation (lost) of TRPV3 in ventral roots associated with injury
9) Confidence 0.39 Published 2007 Journal BMC Neurol Section Body Doc Link PMC1892784 Disease Relevance 0.64 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox